In the last 10 years, the discovery of high mutation rate of B-Raf Proto-Oncogene (BRAF) in melanoma provides the patients with the choice of drugs targeting BRAF that is involved in mitogen-activated protein kinase (MAPK) pathway, which has significantly improved the patients’ survival2,3. Here, BRAF is linked to melanoma.